Diagnosing an insulinoma starts with confirming that your body is producing too much insulin on its own, then pinpointing where the tumor is in the pancreas. The process typically unfolds in three stages: recognizing the pattern of symptoms, running blood tests during a supervised fast, and using imaging to locate the tumor before surgery.
Recognizing the Symptom Pattern
Before any lab work happens, doctors look for a classic clinical pattern called Whipple’s triad. It has three parts: you experience symptoms of low blood sugar (shakiness, confusion, sweating, heart pounding), a blood test taken during those symptoms confirms your glucose is actually low, and eating or drinking something sugary makes the symptoms go away quickly. All three must be present. Many conditions can cause one or two of these, but the full triad narrows the list considerably and triggers a more formal workup.
Insulinoma symptoms tend to appear after fasting or exercise, when the body would normally dial insulin production down. The tumor doesn’t get that signal. It keeps releasing insulin, which drives blood sugar dangerously low. Some people go months or years with episodes misattributed to anxiety, seizure disorders, or psychiatric conditions before anyone checks for an insulin-producing tumor.
The 72-Hour Supervised Fast
The cornerstone of diagnosis is a prolonged supervised fast, typically lasting up to 72 hours in a hospital setting. You stop eating, and medical staff draw blood at regular intervals to measure glucose, insulin, and several related markers. The goal is to provoke a hypoglycemic episode under controlled conditions so the lab can catch what your pancreas is doing at that exact moment.
Diagnosis requires a specific combination of findings when your blood sugar drops below 55 mg/dL:
- Insulin at or above 3 µIU/mL. In a healthy person, insulin would be nearly undetectable at that glucose level. Using this lower threshold catches about 98% of insulinomas, compared to 91% when using the older cutoff of 5 µIU/mL.
- C-peptide at or above 0.6 ng/mL. C-peptide is a byproduct released in equal amounts whenever your pancreas makes insulin. An elevated level proves the insulin is coming from your own body, not from an external injection.
- Proinsulin at or above 5 pmol/L. This is the raw precursor your pancreas converts into insulin. Insulinomas are especially leaky with proinsulin. Research evaluating these thresholds found that a proinsulin level of 22 pmol/L or higher perfectly separated insulinoma patients from healthy controls, with 100% sensitivity and specificity.
Most insulinomas reveal themselves within 48 hours of fasting. Many trigger hypoglycemia much sooner. Not everyone needs the full 72 hours.
Shortening the Fast With a Ketone Marker
Some centers now use a shortcut. When you fast, your body normally switches to burning fat for fuel, which produces ketones. Insulinoma blocks that switch because excess insulin keeps the body locked in sugar-burning mode. By measuring a ketone called beta-hydroxybutyrate, doctors can sometimes end the fast early. If beta-hydroxybutyrate rises above 2.7 mmol/L, an insulinoma is effectively ruled out and the fast can stop. In a Cleveland Clinic study of 21 confirmed insulinoma patients, beta-hydroxybutyrate never exceeded 0.8 mmol/L, showing just how reliably the tumor suppresses ketone production.
Ruling Out Other Causes
Elevated insulin with low blood sugar doesn’t automatically mean a tumor. Two important mimics need to be excluded. The first is someone secretly taking insulin injections, whether intentionally or through a medication error. In that scenario, insulin levels are high but C-peptide is low, because injected insulin doesn’t come with C-peptide attached. That mismatch gives it away.
The second mimic is harder to catch. Certain diabetes medications (sulfonylureas and similar drugs) stimulate the pancreas to release its own insulin, producing a blood test pattern that looks identical to an insulinoma: high insulin, high C-peptide, high proinsulin. The only way to tell the difference is a drug screen. A blood or urine test specifically checking for these medications is a standard part of the workup.
The Glucagon Stimulation Test
In some cases, doctors use a glucagon stimulation test as a supplementary tool. Glucagon is a hormone that tells the liver to release stored sugar. After an injection of glucagon, a healthy person’s blood sugar rises and then settles back to normal. In someone with an insulinoma, the initial rise looks normal, but the tumor responds to that glucose spike by flooding the bloodstream with even more insulin. The result is an exaggerated crash, with blood sugar dropping to hypoglycemic levels between 90 and 180 minutes after the injection. In a study of 14 insulinoma patients, 10 of 14 showed an abnormally large insulin spike in response to glucagon.
Locating the Tumor With Imaging
Once blood tests confirm the diagnosis, the next challenge is finding the tumor. Insulinomas are small, often less than 2 centimeters, and sit inside or on the surface of the pancreas. Over 90% are benign and solitary, which means surgery can be curative if the surgeon knows exactly where to look.
Two imaging methods carry the most weight. Contrast-enhanced CT scanning, particularly modern thin-slice, multi-phase protocols, detects insulinomas with a sensitivity between 65% and 94%, depending on the technique and tumor size. Endoscopic ultrasound, where an ultrasound probe is passed through the mouth into the stomach and duodenum to get right next to the pancreas, achieves 82% to 94% sensitivity with a specificity of 95%. When CT and endoscopic ultrasound are combined, studies report a detection rate approaching 100%.
MRI is sometimes used as well, particularly when CT is inconclusive or when radiation exposure is a concern. Earlier MRI protocols had disappointing detection rates, but newer techniques have closed the gap significantly.
When Standard Imaging Falls Short
In a small percentage of cases, CT, MRI, and endoscopic ultrasound all fail to pinpoint the tumor. This is where the selective arterial calcium stimulation test comes in. Calcium stimulates insulin release specifically from tumor cells. During the procedure, calcium is injected into the arteries that supply different regions of the pancreas, one artery at a time, while blood samples are drawn from a vein draining the liver. A greater than fourfold increase in insulin concentration after calcium injection into a particular artery pinpoints the tumor’s location to the region that artery feeds. The test has a sensitivity around 93% and is especially useful for patients with multiple small tumors or prior inconclusive imaging.
Screening for a Genetic Link
Most insulinomas appear on their own, but a subset is linked to a hereditary condition called MEN1 (Multiple Endocrine Neoplasia type 1). People with MEN1 are prone to tumors in multiple endocrine glands, including the pancreas, parathyroid, and pituitary. Insulinomas tied to MEN1 tend to be multifocal, meaning several tumors scattered throughout the pancreas rather than a single nodule. This changes the surgical approach considerably, often requiring more extensive removal of pancreatic tissue.
Genetic testing for MEN1 is recommended for all young patients diagnosed with an insulinoma. It should also be considered if you have a personal or family history of other endocrine tumors, unexplained high calcium levels, or pituitary problems. If MEN1 is confirmed, ongoing screening for insulinomas and other endocrine tumors becomes a long-term part of care.